Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sample size calculation for the Power Model for dose proportionality studies.

Venkat S Sethuraman1, Sergei Leonov, Lisa Squassante

  • 1Biostatistics and Statistical Reporting, Novartis Pharmaceuticals, Florham Park, NJ 07932, USA. venkat.sethuraman@novartis.com

Pharmaceutical Statistics
|February 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Fosgonimeton in mild-to-moderate Alzheimer's disease.

Journal of Alzheimer's disease reports·2025
Same author

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome using a Delphi Panel.

medRxiv : the preprint server for health sciences·2025
Same author

Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS).

Journal of neurodevelopmental disorders·2023
Same author

Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.

JAMA psychiatry·2022
Same author

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA<sub>A</sub>-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.

Journal of neurodevelopmental disorders·2022
Same journal

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
See all related articles

This study introduces sample size calculations for the Power Model, a statistical method for assessing pharmacokinetic dose proportionality. This approach offers a more informative way to evaluate dose proportionality compared to traditional ANOVA models.

Area of Science:

  • Pharmacokinetics and Pharmacometrics
  • Statistical Modeling in Drug Development

Background:

  • Assessing pharmacokinetic dose proportionality is crucial for drug development.
  • Traditional ANOVA models have limitations in evaluating dose proportionality.
  • The mixed effects Power Model offers a more informative statistical approach.

Purpose of the Study:

  • To derive analytical sample size calculations for the Power Model.
  • To provide methods for various study designs including crossover, incomplete block, and parallel groups.
  • To enhance the statistical rigor in pharmacokinetic dose proportionality assessments.

Main Methods:

  • Development of analytical sample size derivations.
  • Application to the mixed effects Power Model framework.

Related Experiment Videos

  • Consideration of diverse clinical trial designs.

    • Main Results:

    • Novel analytical formulas for sample size determination are presented.
    • The derivations are applicable to crossover, incomplete block, and parallel group designs.
    • These methods support robust pharmacokinetic dose proportionality analysis.

    Conclusions:

    • The proposed sample size derivations facilitate the efficient application of the Power Model.
    • This work provides essential statistical tools for pharmacokinetic study design.
    • Accurate sample size planning improves the reliability of dose proportionality assessments.